EML4-ALK Translocation Predicts Better Outcome in Lung Adenocarcinoma Patients with Wild-Type EGFR  Shang-Gin Wu, MD, Yao-Wen Kuo, MD, Yih-Leong Chang,

Slides:



Advertisements
Similar presentations
Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,
Advertisements

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.
Development of Renal Cysts after Crizotinib Treatment in Advanced ALK-Positive Non– Small-Cell Lung Cancer Yen-Ting Lin, MD, Yu-Fen Wang, MD, James Chih-Hsin.
Su K. Metcalfe, MD, MPH, Michael T
Jarrod D. Predina, BA, Matthew M. Puc, MD, Meredith R
Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung  Sai-Hong.
Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations 
Non–Small Cell Lung Cancer at the Extremes of Age: Impact on Diagnosis and Treatment  William C Nugent, MD, Mark T Edney, BA, Paul G Hammerness, BA, Bradley.
Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,
Chee Khoon Lee, PhD, Johnathan Man, M. B. B. S
Sleep Apnea and Risk of Deep Vein Thrombosis: A Non-randomized, Pair-matched Cohort Study  Kun-Ta Chou, MD, Chin-Chou Huang, MD, Yuh-Min Chen, MD, PhD,
A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R 
Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations
James B. Yu, MD, Lynn D. Wilson, MD, MPH, Frank C. Detterbeck, MD 
ALK FISH and IHC: You Cannot Have One without the Other
Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer  Wolf Köster, MD, Andrea Heider, MD, Norbert.
Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas  Yiliang Zhang, MD, Rui Wang, MD, PhD, Yuan.
Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 
Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.
Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer  Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.
Significance of P53 and Rb protein expression in surgically treated non-small cell lung cancers  Yung-Chie Lee, MD, PhD, Yih-Leong Chang, MD, Shi-Ping.
Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Epidermal Growth Factor Receptor Mutations in Small Cell Lung Cancer: A Brief Report  Tsu-Hui Shiao, MD, Yih-Leong Chang, MD, Chong-Jen Yu, MD, PhD, Yeun-Chung.
Epidermal Growth Factor Receptor Mutations in 510 Finnish Non–Small-Cell Lung Cancer Patients  Satu Mäki-Nevala, MSc, Mikko Rönty, MD, Mike Morel, MBiolSci,
Coexistence of the BRAF Mutation and EGFR Exon 20 Insertion in a Patient with Lung Adenocarcinoma  Lih-Chyun Chang, MD, Kuan-Yu Chen, MD, PhD, Jin-Yuan.
Prognostic Factors in Completely Resected Node-Negative Lung Adenocarcinoma of 3 cm or Smaller  Jung-Jyh Hung, MD, PhD, Yi-Chen Yeh, MD, Yu-Chung Wu,
Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.
Jarrod D. Predina, BA, Matthew M. Puc, MD, Meredith R
Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,
Predictors of Death, Local Recurrence, and Distant Metastasis in Completely Resected Pathological Stage-I Non–Small-Cell Lung Cancer  Jung-Jyh Hung, MD,
Effusion Immunocytochemistry as an Alternative Approach for the Selection of First-Line Targeted Therapy in Advanced Lung Adenocarcinoma  Tzu-Hsiu Tsai,
A Novel EML4-ALK Variant: Exon 6 of EML4 Fused to Exon 19 of ALK
Jeffrey Bradley, MD, Issam El Naqa, PhD  Journal of Thoracic Oncology 
Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors  Benny Weksler, MD, Anthony Holden, MD, Jennifer.
Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion–Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations.
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations  Chao-Hua.
Erik Jakobsen, Maria Iachina, Karen Ege Olsen, Anders Green 
Non–Small Cell Lung Cancer at the Extremes of Age: Impact on Diagnosis and Treatment  William C Nugent, MD, Mark T Edney, BA, Paul G Hammerness, BA, Bradley.
Does Granulocyte Colony–Stimulating Factor Affect Survival in Patients with Advanced Non-small Cell Lung Cancer?  Goulnar Kasymjanova, MD, Harvey Kreisman,
Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature  Caicun Zhou, MD, PhD, Luan Di Yao, MD 
High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer  Heounjeong Go, MD, Yoon Kyung Jeon, MD, PhD, Hyo Jin.
Jessica J. Lin, MD, Stephanie Cardarella, MD, Christine A
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non–Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis  Bin-Chi Liao,
Thoracoscopic Lobectomy Produces Long-Term Survival Similar to That with Open Lobectomy in Cases of Non–Small Cell Lung Carcinoma: A Propensity-Matched.
Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemonaive, Advanced, Non- small Cell Lung Cancer Patients Aged 70 Years or Older  Yuh-Min Chen,
Phase II Study of the Histone Deacetylase Inhibitor Romidepsin in Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30304)  Gregory A. Otterson,
Tumor-Stroma Ratio Is an Independent Predictor for Survival in Esophageal Squamous Cell Carcinoma  kai Wang, MD, Wei Ma, MD, Jianbo Wang, MD, Liang Yu,
Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations 
Forced Expiratory Volume in One Second as a Prognostic Factor in Advanced Non- small Cell Lung Cancer  Jin Hwa Lee, MD, PhD, Eun Mi Song, MD, Yun Su Sim,
Epidermal Growth Factor Receptor Mutation Status in Stage I Lung Adenocarcinoma with Different Image Patterns  Kuo-Hsuan Hsu, MD, Kun-Chieh Chen, MD,
Peripheral Direct Adjacent Lobe Invasion Non-small Cell Lung Cancer Has a Similar Survival to That of Parietal Pleural Invasion T3 Disease  Hao-Xian Yang,
Role of Postoperative Radiotherapy in Nonlocalized Thymoma
Different Efficacies of Erlotinib and Gefitinib in Taiwanese Patients with Advanced Non- small Cell Lung Cancer: A Retrospective Multicenter Study  Wen-Chien.
Chemotherapy Response in East Asian Non-small Cell Lung Cancer Patients Harboring Wild-Type or Activating Mutation of Epidermal Growth Factor Receptors 
Pulmonary Resection for Metastases from Colorectal Cancer
Michael Hsie, MD, Stefania Morbidini-Gaffney, MD, Leslie J
Prognostic Significance of CT-Determined Sarcopenia in Patients with Small-Cell Lung Cancer  Eun Young Kim, MD, Young Saing Kim, MD, Inkeun Park, MD,
Surgical outcomes after cardiac surgery in liver transplant recipients
Safety and Efficacy of First-Line Bevacizumab Plus Chemotherapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer:
Bcl-2-Like Protein 11 Deletion Polymorphism Predicts Survival in Advanced Non–Small- Cell Lung Cancer  Jih-Hsiang Lee, MD, Yu-Lin Lin, MD, Wei-Hsun Hsu,
Efficacy and Safety of Cisplatin/Pemetrexed Versus Cisplatin/Gemcitabine as First-Line Treatment in East Asian Patients with Advanced Non-small Cell Lung.
Effect of Formalin Fixation on Tumor Size Determination in Stage I Non-Small Cell Lung Cancer  Po-Kuei Hsu, MD, Hsu-Chih Huang, MD, Chih-Cheng Hsieh,
Good Response to Gefitinib in Lung Adenocarcinoma Harboring Coexisting EML4-ALK Fusion Gene and EGFR Mutation  Yao-Wen Kuo, MD, Shang-Gin Wu, MD, Chao-Chi.
Pleurodesis for primary spontaneous pneumothorax – Authors' reply
Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.
Temporal Trends in Long-Term Survival and Cure Rates in Esophageal Cancer: A SEER Database Analysis  Attila Dubecz, MD, Isabell Gall, MD, Norbert Solymosi,
Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer  James B. Yu, MD, Roy H. Decker, MD, PhD,
Nutrition During Trimodality Treatment in Stage III Non-small Cell Lung Cancer: Not Only Important for Underweight Patients  Barbara S. van der Meij,
Prognostic Significance of Tumor Size in Patients with Stage III Non–Small-Cell Lung Cancer: A Surveillance, Epidemiology, and End Results (SEER) Survey.
Presentation transcript:

EML4-ALK Translocation Predicts Better Outcome in Lung Adenocarcinoma Patients with Wild-Type EGFR  Shang-Gin Wu, MD, Yao-Wen Kuo, MD, Yih-Leong Chang, MD, Jin-Yuan Shih, MD, PhD, Ya-Hui Chen, MSc, Meng-Feng Tsai, PhD, Chong-Jen Yu, MD, PhD, Chih-Hsin Yang, MD, PhD, Pan-Chyr Yang, MD, PhD  Journal of Thoracic Oncology  Volume 7, Issue 1, Pages 98-104 (January 2012) DOI: 10.1097/JTO.0b013e3182370e30 Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Kaplan-Meier survival curve of overall survival of lung adenocarcinoma patients with EML4-ALK (solid line) and without EML4-ALK fusion gene (dashed); the difference was statistically significant (median, 14.7 versus 10.3 months; p = 0.009, by the log-rank test). Journal of Thoracic Oncology 2012 7, 98-104DOI: (10.1097/JTO.0b013e3182370e30) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions